Background: Hematopoietic stem cell transplantation (HSCT) is a popular subtype of transplantation used in different malignant and non-malignant diseases, especially when treatment or therapeutics do not work. Although post-transplantation lymphoproliferative disease (PTLD) is often observed in patients with HSCT, no study on the overall global prevalence rate is available to date. Methodology: In this study, we selected 39 studies from 941 studies from three databases (i.e. PubMed, ScienceDirect, and Google Scholar) to identify the global prevalence rate of PTLD in HSCT. Result: The pooled prevalence was determined as 5.6% (95% CI: 5.0 to 6.3) and rose further to 12.4% (95%CI: 10.2 to 14.7) after excluding outlier studies. The quality of the studies was high as well. The prevalence of death cases among the HSCT was determined as 0.6% (95%CI: 0.4 to 0.9). PTLD was prevalent the most in allogenic HSCT (i.e. 5.6% (95% CI: 4.9 to 6.3)) and within the European region (i.e. 27.1% (95%I: 21.4 to 32.8)). Among risk factors, HLA mismatch was reported in most of the studies. Conclusion: This study assessed and discussed the overall global prevalence of PTLD in HSCT patients, continent-based prevalence, and risk factors that can be helpful in finding the possible prevention mechanism of PTLD and implementing individualized treatment approaches based on the treatment availability during HSCT.
Shahad Saif Khandker (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: